In a randomized clinical trial in which resected stage III–IV melanoma patients were treated with peptide-based vaccination and IFN-α2b, with or without dacarbazine preconditioning, we have used mFC to reveal parameters correlating with relapse-free survival. This evidence concerns the gene IFNA2 and melanoma.